S2Medical AB (publ)
STO:S2M
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.0085
0.1295
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
S2Medical AB (publ)
Total Receivables
S2Medical AB (publ)
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Total Receivables
kr1.7m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
O
|
OssDsign AB
STO:OSSD
|
Total Receivables
kr25.8m
|
CAGR 3-Years
48%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Total Receivables
kr188m
|
CAGR 3-Years
56%
|
CAGR 5-Years
29%
|
CAGR 10-Years
32%
|
|
|
D
|
Doxa AB
STO:DOXA
|
Total Receivables
kr23.7m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
61%
|
CAGR 10-Years
24%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Total Receivables
kr30.7m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Total Receivables
€153.6m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
S2Medical AB (publ)
Glance View
S2Medical AB engages in research and development in biotechnology. The company is headquartered in Linkoping, Ostergotland. The company went IPO on 2018-11-28. The firm focuses on developing products for healing burns and chronic wounds, from debridement and granulation to reepithelialization. The firm's product portfolio includes INSTAQRETT, a sterile single-use mechanical debridement tool, the Epiprotect product line based on its collagen-mimicking Eiratex material, which includes EPIPROTECT Safestop, a blood-stilling membrane dressing, EPIPROTECT 2117, a synthetic substitute to allografts and xenografts, EPIPROTECT ULCER, dressing for treating ulcers, as well as INSTABIND bandages and Instagraft, a single-use medical device designed to treat chronic wounds with microtransplants from the patient's own skin without creating any new wounds. The firm is also the official distributor of Silverlon antimicrobial dressings for Nordic countries. In addition, it operates the S2Clinic, a wound healing center in Sweden.
See Also
What is S2Medical AB (publ)'s Total Receivables?
Total Receivables
1.7m
SEK
Based on the financial report for Jun 30, 2024, S2Medical AB (publ)'s Total Receivables amounts to 1.7m SEK.
What is S2Medical AB (publ)'s Total Receivables growth rate?
Total Receivables CAGR 5Y
-8%
Over the last year, the Total Receivables growth was -93%. The average annual Total Receivables growth rates for S2Medical AB (publ) have been -10% over the past three years , -8% over the past five years .
You don't have any saved screeners yet
